An interventional study of Spatial emanator outdoor and Spatial emanator indoor in Malaria, sponsored by Macfarlane Burnet Institute for Medical Research and Public Health Ltd. Not yet recruiting at 1 site in Papua New Guinea. Open to participants aged 9 Years to 14 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Macfarlane Burnet Institute for Medical Research and Public Health Ltd · Not applicable, Interventional, and Prevention
Malaria cases are increasing in Papua New Guinea, partly because insecticide-treated nets do not fully protect people, especially from mosquitoes that bite outdoors. Spatial emanators are new devices that release insecticide into the air to repel or kill mosquitoes. This study will test whether these devices reduce malaria infections in rural villages in Madang Province by comparing households using indoor or outdoor devices with those without them. The results will help guide national malaria control strategies.
The WinMal trial is a large-scale cluster randomised control trial investigating whether spatial emanators reduce transmission of malaria infections. The study is being conducted with 150 rural villages in Bogia, Sumkar, Madang and Rai Coast districts of Madang Province, Papua New Guinea.
The trial will address the question: 'Do Guardian spatial emanators reduce malaria transmission when deployed in protected outdoor spaces or inside houses in PNG?'
The trial will evaluate the effectiveness, acceptability and feasibility of Guardian SE deployed indoors and outdoors for malaria prevention in PNG.
The WinMal trial will provide evidence to guide PNG National Department of Health decisions on how spatial emanators could be deployed alongside ITNs to address gaps in protection from outdoor biting.
1,184 studies on the registry are indexed under Malaria; 79 are open to participants now.
This study's planned enrollment of 4,350 is above the median of 252 across 937 interventional studies indexed under Malaria.
Browse Malaria studies →Macfarlane Burnet Institute for Medical Research and Public Health Ltd is the lead sponsor of 16 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Guardian spatial emanators deployed in protected outdoor spaces, households will continue to use ITNs as per routine National Malaria Control Program
Device: Spatial emanator outdoor
Guardian spatial emanators deployed inside houses, households will continue to use ITNs as per routine National Malaria Control Program
Device: Spatial emanator indoor
No spatial emanators deployed, households will continue to use ITNs as per routine National Malaria Control Program
Guardian spatial emanators deployed in protected outdoor spaces
Guardian spatial emanators deployed inside houses
Effectiveness of Guardian Spatial Emanator
Time to first Plasmodium spp. infection detected by PCR at monthly follow-up visits or symptomatic ad-hoc visit between follow-ups over the 12-month intervention period in cohort participants from the core of the clusters.
Time frame: 12 months
Effectiveness of Guardian Spatial Emanator
Time to first PCR-confirmed P. falciparum infection over the 12 months of follow-up. Time to first PCR-confirmed P. vivax infection over the 12 months of follow-up.
Time frame: 12 months
Effectiveness of Guardian Spatial Emanator
Time to first PCR-confirmed Plasmodium spp infection over the first 6 months of follow-up. Time to first PCR-confirmed P. falciparum infection over the first 6 months of follow-up. Time to first PCR-confirmed P. vivax infection over the first 6 months of follow-up.
Time frame: 6 months
Effectiveness of Guardian Spatial Emanator
Incidence of PCR-confirmed Plasmodium spp infections (first-time \& recurrent together) in first 6m \& full 12m. Incidence of PCR-confirmed Pf infections (first-time \& recurrent together) in first 6m \& full 12m. Incidence of PCR-confirmed Pv infections (first-time \& recurrent together) in first 6m \& full 12m Incidence of clinical episodes of malaria (first-time \& recurrent together) in first 6m \& full 12m Incidence of Pf clinical episodes of malaria (first-time \& recurrent together) in first 6m \& full 12m Incidence of Pv clinical episodes of malaria (first-time \& recurrent together) in first 6m \& full 12m Incidence of new Pf blood stage infections (molecular force of blood-stage infection - Pf molFOB) in first 6m \& full 12m Incidence of new Pv blood stage infections (molecular force of blood-stage infection - Pv molFOB) in first 6m \& full 12m Incidence of new blood stage infections (molecular force of blood-stage infection for Pf and Pv molFOB combined) in first 6m \& full 12m
Time frame: 12 months
Difference between indoor and outdoor arms
Time to first Plasmodium spp. infection detected by PCR at monthly follow-up or symptomatic ad-hoc visit between follow-ups visits over the 12-month intervention period in cohort participants from the core of the clusters.
Time frame: 12 months
Sensitivity of the estimates for epidemiological outcomes
Spillover-adjusted estimates of intervention effectiveness for epidemiological endpoints, incorporating data from cluster buffer zone participants.
Time frame: 12 months
Anopheles species composition
Anopheles species composition in a subset of clusters, in the pre-deployment baseline period and at the end of the intervention.
Time frame: 12 months
Presence of insecticide resistance mutations
Prevalence of insecticide resistance markers in a subset of clusters in the pre-deployment baseline period and at the end of the intervention.
Time frame: 12 months
Acceptability of spatial emanators
Qualitative outcomes from Photovoice methodology, and associated focus group discussions with community members, followed by thematic analysis of drivers of behaviour change, barriers and enablers of spatial emanator acceptance and consistent use.
Time frame: 12 months
Feasibility of spatial emanators
Qualitative outcomes from key informant interviews with key study staff and health system stakeholders at district, provincial, and national level followed by descriptive summary of barriers and enablers to distribution, implementation \& scale-up.
Time frame: 12 months
Cost effectiveness of Guardian spatial emanators
The costs of deploying spatial emanators (either indoor or outdoor) and the incremental cost-effectiveness ratios when compared with current practice.
Time frame: 12 months
Self-reported adverse events
Incidence of self-reported adverse events (AEs) and/or serious adverse events (SAEs) assessed as possibly or likely related to Guardian spatial emanators among cohort participants (through monthly follow-up) and wider community through passive surveillance.
Time frame: 12 months
Coverage, attrition and re-location of spatial emanators
Proportion of households with emanators in place at scheduled monitoring visits, the attrition rate per cluster per scheduled monitoring visit period, timing of redistribution events recorded per cluster.
Time frame: 12 months
Transfluthrin quantity, installation environment and bioefficacy
Mass percent transfluthrin retained in the spatial emanators related to installation environment and bioefficacy measure/s (e.g., knock down and mortality of colony mosquitoes exposed to spatial emanators).
Time frame: 12 months
Plan to share: Yes
No publications or documents are linked to this record.
Start is estimated for Feb 2027; primary completion for Oct 2028, 20 months later.
Of 95 non-industry interventional studies with no phase under Malaria, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 35. This study's planned 20 months is below that.
Counting every sponsor, half of 101 studies reached it within 23 months; a quarter within 8 and three quarters within 33.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Macfarlane Burnet Institute for Medical Research and Public Health Ltd